熱門資訊> 正文
艾伯维启动耗资7000万美元的研发建设和制造中心扩建
2025-10-01 04:44
- AbbVie (NYSE:ABBV) has broken ground on a $70M expansion of an existing site in Worcester, Mass., that serves as a biologics R&D center and manufacturing facility.
- The company said the additional space will boost its biologics manufacturing capacity. The plan also calls for a three-story building for laboratory, warehouse, and office space. Also, the new facilities will speed up the transfer of some oncology therapies from Europe to the U.S.
- During its Q1 earnings call in late April, AbbVie management said it would invest $10B to improve its supply chain in the US.
More on AbbVie
- AbbVie For Healthy Dividend Growth
- AbbVie: Best Time To Sell In 5 Years (Rating Downgrade)
- AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- AbbVie launching ovarian cancer therapy Elahere in UK at US list price
- SA analyst upgrades/downgrades: AMD, SNOW, MU, and ABBV
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
